Surgery Websites
T32 Surgical Oncology »  Faculty Mentors »  Regulatory Sciences »  Deanna Kroetz, PhD
Deanna Kroetz, PhD

Deanna Kroetz, PhD

  • Professor, Bioengineering and Therapeutic Sciences
Open Popup
  Institution  
  Degree    
  Dept or School    
  End Date    
  • National Cancer Institute, Bethesda, MS
  • Drug Metabolism
  • 06/1993
  • University of Washington, Seattle, WA
  • PhD
  • Pharmaceutics
  • 08/1990
  • Ohio State University, Columbus, OH
  • BS
  • Pharmacy
  • 06/1985
  • The overarching goal of the Kroetz laboratory is to understand the molecular basis of interindividual variability in drug response and toxicity. Genomic association studies are used to identify genes and pathways involved in common toxicities associated with cancer therapy, including taxane-induced peripheral neuropathy and bevacizumab-induced hypertension. Functional genomic studies are then used to define the role of these genes and pathways in the dose-limiting toxicities. A second area of research is on the role of ABC transporters in drug resistance and physiologic function. Ongoing efforts include cryo-EM studies of MRP4 and investigation of MRP4 in resistance to immunotherapy.
      Award  
      Confired By    
      Date    
  • Rawls-Palmer Progress in Medicine Award
  • American Society for Clinical Pharmacology & Therapeutics ASCPT
  • 2022 - 2022
  • Jere E. Goyan Presidential Chair
  • Advancement of Pharmacy
  • 2020 - 2020
  • Bristol-Myers Squibb Mentorship in Clinical Pharmacology Award
  • American College of Clinical Pharmacology
  • 2020 - 2020
  • Deans Apple Award for Teaching
  • UCSF School of Pharmacy
  • 2020 - 2020
  • Mentor Award
  • American Society for Clinical Pharmacology and Therapeutics
  • 2019 - 2019
  • Deans Apple Award for Teaching
  • UCSF School of Pharmacy
  • 2019 - 2019
  • Elected Fellow
  • American Association for the Advancement of Science
  • 2018 - 2018
  • Deans Apple Award for Teaching
  • UCSF School of Pharmacy
  • 2018 - 2018
  • Distinguished Alumnus Award for Excellence in Pharmaceutical Sciences and Research
  • University of Washington School of Pharmacy
  • 2018 - 2018
  • Deans Apple Award for Teaching
  • UCSF School of Pharmacy
  • 2016 - 2016
  • Judith Pool Award for Mentoring
  • Northern California Association for Women in Science
  • 2014 - 2014
  • Deans Apple Award for Teaching
  • UCSF School of Pharmacy
  • 2011 - 2011
  • Deans Apple Award for Teaching
  • UCSF School of Pharmacy
  • 2009 - 2009
  • Elected Fellow, American Association of Pharmaceutical Scientists
  • American Association of Pharmaceutical Scientists
  • 2008 - 2008
  • Named to Faculty of 1000, Pharmacology
  • Pharmacology
  • 2008 - 2008
  • Elected Fellow, High Blood Pressure Research Council of the American Heart Association
  • American Heart Association
  • 2002 - 2002
  • Leon I. Goldberg Young Investigator Award
  • American Society for Clinical Pharmacology and Therapeutics
  • 2002 - 2002
  • American Association of Pharmaceutical Scientists Young Investigator Award in Pharmacokinetics, Phar
  • American Association of Pharmaceutical Scientists
  • 1996 - 1996
  • Josephine S. Failer Alumni Award
  • Ohio State University College of Pharmacy
  • 1995 - 1995
  • Pharmacology Research Associate Training (PRAT) Fellowship
  • Pharmacology Research Associate Training
  • 1991 - 1993
  • National Institute of Health Training Grant Trainee
  • National Institute of Health Training
  • 1987 - 1990
  • Ohio State University Presidential Scholar Eli Lilly Company Achievement Award
  • Cum Laude Graduate Ohio State University College of Pharmacy
  • 1985 - 1985
  • National Pharmaceutical Council Internship Mortar Board Honor Society Rho Chi National Pharmacy Ho
  • National Pharmaceutical Council
  • 1984 - 1984
  • Data provided by UCSF Profiles, powered by CTSI
    ORCID iD: 0000-0001-5997-270X Additional info
    • Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity
      Sponsor:
      Sponsor ID:
      Funding Period:
      Apr 2021
      -
      Mar 2026
      Principal Investigator
    • The Role of Genomics in Postoperative Delirium and Sedation
      Sponsor:
      Sponsor ID:
      Funding Period:
      Oct 2019
      -
      Sep 2022
      Co-investigator leading the genomic analyses
    • Developing Silastic-Silicone for the Local Delivery of Hormonal Therapy to Prevent and Treat Breast Cancer
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jul 2017
      -
      Jun 2022
      Co-Investigator
    • Pharmaceutical Sciences and Pharmacogenomics
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jul 1982
      -
      Jun 2022
      Principal Investigator
    • Pharmacogenomics of Microtubule Targeting Agents
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jul 2015
      -
      Jun 2021
      Principal Investigator
    • Targeting MRP4-Mediated PGE2 Efflux to Improve Sensitivity to Immunotherapy
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jun 2020
      -
      May 2021
      Principal Investigator
    • Individualized Therapy for Recurrent Glioblastoma
      Sponsor:
      Sponsor ID:
      Funding Period:
      Apr 2018
      -
      Mar 2021
      Co-investigator for pharmacology
    Data provided by UCSF Profiles, powered by CTSI
    MOST RECENT PUBLICATIONS FROM A TOTAL OF 130
    Data provided by UCSF Profiles, powered by CTSI
    1. Giacomini KM, Yee SW, Koleske ML, Zou L, Matsson P, Chen EC, Kroetz DL, Miller MA, Gozalpour E, Chu X. New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium. Clin Pharmacol Ther. 2022 09; 112(3):540-561. View in PubMed
    2. Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 Jan; 126(1):162. View in PubMed
    3. Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274. View in PubMed
    4. Bajaj R, Chong LB, Zou L, Tsakalozou E, Ni Z, Giacomini KM, Kroetz DL. Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. AAPS J. 2021 09 15; 23(5):106. View in PubMed
    5. Chua KC, El-Haj N, Priotti J, Kroetz DL. Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies. Basic Clin Pharmacol Toxicol. 2022 Jan; 130 Suppl 1:60-74. View in PubMed
    6. View All Publications

     

    Site Directory
      X